← back to search

Shunli Shen

Sun Yat-sen University · CN
Area of research
Hepatology · Pathology and Forensic Medicine
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cancer Mechanisms and Therapy, Cholangiocarcinoma and Gallbladder Cancer Studies, and Cancer Immunotherapy and Biomarkers.
h-index
30
citations
2,269
works
188
NIH funding
primary concept
Medicine
email

Recent publications

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 35position: middledoi
Xanthium strumarium/gelatin methacryloyl based hydrogels with anti-inflammatory and antioxidant properties for diabetic wound healing via akt/mtor pathway
International Journal of Biological Macromolecules 2025cited by 13position: middledoi
Th17 Cells Secrete TWEAK to Trigger Epithelial–Mesenchymal Transition and Promote Colorectal Cancer Liver Metastasis
Cancer Research 2024cited by 62position: middledoi
FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma
Journal of Hepatology 2024cited by 54position: middledoi
Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial
Clinical Cancer Research 2024cited by 17position: middledoi
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences
Gut 2023cited by 66position: middledoi
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC
Hepatology 2023cited by 52position: middledoi
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
Cell Reports Medicine 2023cited by 44position: middledoi
Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy
Hepatology International 2023cited by 39position: middledoi
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes
Hepatology International 2023cited by 20position: lastdoi
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
Cell Research 2022cited by 100position: middledoi
Targeting tumour-intrinsic N <sup>7</sup> -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy
Gut 2022cited by 78position: middledoi
Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
Cancer Immunology Research 2022cited by 72position: middledoi
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma
Gut 2021cited by 130position: middledoi
Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment
Journal of Experimental & Clinical Cancer Research 2019cited by 101position: middledoi
A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI)
BMC Cancer 2016cited by 109position: middledoi
Risk factors and outcomes of postoperative pancreatic fistula after pancreatico-duodenectomy: an audit of 532 consecutive cases
BMC Surgery 2015cited by 81position: middledoi
Adjuvant antiviral therapy for hepatitis B virus‐related hepatocellular carcinoma after curative treatment: A systematic review and meta‐analysis
Hepatology Research 2015cited by 46position: middledoi
The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma
BMC Cancer 2015cited by 43position: middledoi
Preoperative Aspartate Aminotransferase to Platelet Ratio is an Independent Prognostic Factor for Hepatitis B-Induced Hepatocellular Carcinoma After Hepatic Resection
Annals of Surgical Oncology 2014cited by 104position: firstdoi
Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma
Digestive Diseases and Sciences 2014cited by 70position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Baogang Peng · Bioscience Research6 papers (2014–2023)Yunpeng Hua · Sun Yat-sen University6 papers (2014–2024)Shaoqiang Li · State Key Laboratory of Respiratory Disease5 papers (2014–2023)Jiaming Lai · Chengdu University of Technology4 papers (2014–2023)Shunjun Fu · Zhujiang Hospital4 papers (2014–2016)Sui Peng · Sun Yat-sen University3 papers (2022–2023)Yubin Xie · Shanghai University3 papers (2023–2023)Xuezhen Zeng · Chinese University of Hong Kong3 papers (2022–2023)Xiaoxue Ren · Sun Yat-sen University3 papers (2023–2023)Lijian Liang · Sun Yat-sen University3 papers (2014–2015)Wenjie Hu · Sun Yat-sen University3 papers (2014–2015)Shuling Chen · Jiangsu University of Science and Technology3 papers (2022–2023)Wenxuan Xie · Sun Yat-sen University2 papers (2022–2023)Huanjing Hu · Army Medical University2 papers (2023–2023)Zihao Dai · Dalian Medical University2 papers (2022–2023)Fei Ji · Novartis (Switzerland)2 papers (2015–2016)Xiaoxing Li · Guiyang College of Traditional Chinese Medicine2 papers (2023–2023)Lixia Xu · Westlake University2 papers (2022–2023)Qinghua Cao · Ningbo University2 papers (2015–2019)Jun Yu · University of Geneva2 papers (2021–2023)